First human trial launches for experimental cancer drug targeting HER2 tumors
NCT ID NCT05423977
Summary
This early-stage study is testing a new experimental drug called ZV0203 in patients with advanced HER2-positive solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose and understand how the drug moves through the body. Researchers will enroll about 36 patients to check for side effects and see if the drug shows any early signs of fighting the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
PKUCare Luzhong Hospital
Zigong, Shandong, China
Conditions
Explore the condition pages connected to this study.